Related Experiment Video
Updated: Jan 14, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Health Benefits In 2025: Family Premiums Rise 6 Percent, Large Employers Increase Coverage Of GLP-1s For Weight Loss
Gary Claxton1, Matthew Rae2, Anthony Damico3
1Gary Claxton, KFF, Washington, D.C.
In 2025, employer-sponsored health insurance premiums rose 6%, reaching $26,993 for families. Many workers worry about healthcare costs, with prescription drug prices significantly impacting premium increases.
Area of Science:
- Health Economics
- Employee Benefits
- Healthcare Policy
Background:
- Employer-sponsored health insurance is a primary source of healthcare coverage in the US.
- Rising healthcare costs and prescription drug prices are significant concerns for employers and employees.
- The landscape of health benefits is evolving with new treatments and cost-sharing strategies.
Purpose of the Study:
- To analyze the trends in health insurance premiums and cost-sharing for covered workers in 2025.
- To assess employer perspectives on employee concerns regarding healthcare affordability.
- To examine the coverage of GLP-1 agonists for weight loss and their impact on employer health benefits.
Main Methods:
- Analysis of national survey data on employer-sponsored health benefits.
- Calculation of average annual premiums, worker contributions, and deductibles.
- Examination of employer-reported data on benefit offerings and cost concerns.
Main Results:
- The average annual premium for family health coverage reached $26,993 in 2025, a 6% increase.
- Workers contributed 16% for single and 26% for family coverage, with average deductibles at $1,886 for single coverage.
- 19% of large firms covered GLP-1 agonists for weight loss, and 45% of employers noted high employee concern about cost-sharing affordability.
Conclusions:
- Rising health insurance premiums and worker cost-sharing remain significant financial burdens.
- Employer concerns about prescription drug costs and employee affordability are prominent.
- The coverage of newer, high-cost medications like GLP-1 agonists presents new challenges for health benefit plans.
More Related Videos
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
03:05Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
Published on: November 21, 2025
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: Glinides
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity